Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single Arm, Multicenter Study to Evaluate the Pharmacodynamics and Safety of Re-Treatment With ALXN2220 in Patients With Transthyretin Amyloid Cardiomyopathy

NCT07213583 is registered in ClinicalTrials.gov with Neurimmune AG as lead sponsor.

NCT NCT07213583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07213583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single Arm, Multicenter Study to Evaluate the Pharmacodynamics and Safety of Re-Treatment With ALXN2220 in Patients With Transthyretin Amyloid Cardiomyopathy
Lead sponsor
Neurimmune AG
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 28, 2025
Completion date
October 31, 2026
Enrollment
35 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

amyloid transthyretin cardiomyopathy